Coinspeaker
GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial
WHO accidentally posted a draft summary of remdesivir trial studies. As soon as the organization realized the mistake, it deleted the post. But Gilead (GILD) stock plunged.
GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial
32 total views, 1 views today
Login to Syn with Twitter
OR Login / signup
Please Enter a Comment
Load more (0)